The Effect of Contrast Agent on Endothelial Function in Healthy Men

Overview

Contrast medium is essential for diagnosis of many diseases. However, recent studies showed that contrast agents can induce renal injury and is associated with poor long-term clinical outcome, especially in diabetes. To date, no data are available on the relationship between contrast medium and endothelial function. Endothelial dysfunction is known to precede atherosclerosis and is considered a risk marker for future development of cardiovascular disease. Therefore, we hypothesized that contrast agents may induce endothelial dysfunction in healthy men. In addition, we hypothesized that contrast induced endothelial dysfunction via free radicals. Thus, we also test alpha-lipoic acid whether or not protect endothelial dysfunction induced by contrast agents.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Health Services Research
    • Masking: Single (Participant)
  • Study Primary Completion Date: July 2015

Interventions

  • Other: Contrast agent

Arms, Groups and Cohorts

  • Experimental: contrast group (Ioversol)
    • Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes
  • Placebo Comparator: Placebo group
  • Other: alpha-lipoic acid group
    • Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups.

Clinical Trial Outcome Measures

Primary Measures

  • The endothelial dysfunction and the protective role of alpha-lipoic acid
    • Time Frame: 6 months

Secondary Measures

  • The apoptosis of endothelial progenitor cell
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • healthy men – 20 yr < = age < = 30 yr – 20 < = body mass index < = 25 Exclusion Criteria:

  • age < 20 yr or > 30 yr – dysfunction for liver, renal, and heart. – other diseases such as diabetes, hypertension, thyroid disease

Gender Eligibility: Male

Minimum Age: 20 Years

Maximum Age: 30 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Xiang Guang-da
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Xiang Guang-da, Director of Endocrinol and Metab – Wuhan General Hospital of Guangzhou Military Command

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.